Teduglutide Powder

Xi'an Faithful BioTech Co., Ltd: Your Trusted Teduglutide Powder Manufacturer & Supplier

GLP-2 is a peptide secreted by distal intestinal L cells. Teduglutide Powder is a glucagon like peptide-2 (GLP-2) analogue, a naturally occurring hormone that reduces gastric emptying and secretion, and regulates the growth, proliferation, and repair of intestinal epithelial cells. Research has found that Xi'an Faithful BioTech Co., Ltd provides Teduglutide(ALX-0600), which can significantly increase the number of small intestinal endometrial cells and further enhance the ability of small intestine absorption. At the same time, it can also maintain the integrity of the small intestinal mucosal wall and reduce the occurrence of various types of diarrhea.

Teduglutide Powder Introduction

Short bowel syndrome is a relatively rare disease, in which patients are unable to absorb nutrients, vitamins, and water from food due to the loss of most intestinal function, and can only rely on artificially produced special nutrition supply machines to provide daily essential nutrients. However, parenteral nutrition not only seriously affects the quality of life of patients, but also often leads to serious complications such as intestinal infections, excessive bacterial proliferation in the small intestine, hepatotoxicity, and biliary tract diseases. Research has shown that GLP-2 can increase intestinal and portal vein blood flow and inhibit gastric acid secretion, while Teduglutide Powder is a structurally similar product to glucagon like peptide-2 (GLP-2) and a naturally occurring hormone that can bind to glucagon like peptide-2 receptors located in intestinal endocrine cells, intestinal subepithelial myofibroblasts, and submucosal and intestinal muscle plexus neurons. Furthermore, it reduces gastric emptying and secretion, regulates the growth, proliferation, and repair of intestinal endometrial cells. In clinical practice, it has become the preferred product for treating short bowel syndrome caused by severe intestinal diseases or large intestinal resection leading to the inability to absorb nutrients.

Specifications

Why Choose Us? 

Chose our API Teduglutide because we provide far more than the product itself, but a comprehensive solution aimed at helping patients with short bowel syndrome regain their lives. Its core competitiveness stems from the excellent curative effect verified by a large number of clinical practices around the world-it can directly act on intestinal mucosa, promote its structural repair and functional adaptation, fundamentally improve its independent absorption ability of water and nutrients, thus significantly reducing or even completely getting rid of patients' lifelong dependence on nutrition, which is a key step towards life autonomy and freedom.

We deeply understand the challenges of this treatment journey, so we have built an unparalleled all-round support system. From product purity, transportation process and comprehensive service, we will always walk side by side with you. More importantly, we have the highest standard of commitment to safety and a strict risk management system to ensure your maximum benefit. Therefore, choosing us means that you have chosen a long-term partner who is based on solid curative effect, patient-centered and completely trustworthy. Our common goal is to realize the therapeutic value and ultimately improve the quality of life of every patient.

If you are interested in our Teduglutide raw​​​​​​​ powder, please leave us a message via email：sales8@faithfulbio.com.

Teduglutide's risk experiment

In order to ensure that the benefits of patients applying Teduglutide powder outweigh their potential risks, FDA has approved its marketing through risk assessment and mitigation strategies. In order to study its long-term safety, FDA also requires manufacturers to conduct long-term follow-up investigation and study in routine clinical environment to further evaluate whether it will increase potential cancer or other risks, and the follow-up period should not be less than 10 years.

Two clinical trials and extended trials evaluated its safety, effectiveness and tolerance. Patients in the trial were randomly divided into ALX 0600 treatment group and placebo group. To evaluate the number of patients (clinical response) whose weekly parenteral nutrition capacity decreased by at least 20% after 20-24 weeks of treatment and the average decreased parenteral nutrition capacity after 24 weeks of treatment. The results showed that 46% and 63% of patients treated with Gattex achieved clinical response, while the percentage of patients in placebo group was 6% and 30%. Parenteral nutrition decreased by 2.5 L/ week and 4.4 L/ week in the ALX 0600 USP EP BP treatment group, and by 0.9 L/ week and 2.3 L/ week in the placebo group.

The extended trial followed up patients who received an additional 28 weeks of Revestive treatment. The results showed that the average parenteral nutrition capacity of patients decreased by 4.9 L/ week and 5.2 L/ week after continuous treatment for one year. In the extended trial, 6 patients got rid of parenteral nutrition support when receiving Revestive treatment.

Quality Control:

Packaging and Transportation:

After-Sales Service: 

Qualification Certification:

Transaction Feedback: 

Exhibition: 

Contact us

By choosing our Teduglutide Powder, you are not only choosing an effective ingredient, but also:

A globally proven therapeutic hope

An all-round and temperature-sensitive patient support ecosystem.

A professional and reliable clinical partner.

A firm commitment to improving drug accessibility

We are committed to working with you to help every patient with short bowel syndrome move towards a more independent and high-quality new life.

If you have a new purchase plan, please contact me by email:sales8@faithfulbio.com